Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...
Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH ...
There are no FDA-approved therapies for the treatment of OI.
Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...
Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced that the first patient has been ...
Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart ...
Kallyope, a late-stage biotechnology company focused on developing innovative migraine and metabolic disease therapies for ...
Long COVID affects an estimated 65 million people worldwide and can damage the brain, heart, blood vessels, and immune system ...
US FDA accepts Camurus’ resubmission of NDA for Oclaiz for treatment of acromegaly: Lund, Sweden Monday, January 12, 2026, 15:00 Hrs [IST] Camurus, an international, science-led ...
MedPage Today on MSN
GLP-1 Drug Market Changes; Wegovy Pill Hits Shelves; Hypercortisolism Drug Rejected
And in a phase III trial win, Foresee Pharmaceuticals said its long-acting gonadotropin-releasing hormone agonist leuprolide ...
Drug major Zydus Lifesciences Limited has received a key regulatory clearance from the Subject Expert Committee (SEC) ...
Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback